Hyderabad, Oct 31 (UNI) Suven Life Sciences Ltd today announced that two of their New Chemical Entities (NCEs) for treating disorders associated with Neurodegenerative diseases were granted patents in Australia and New Zealand.
These patents would be valid till 2022, a press release here said.
The granted claims of these patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of diseases like Alzheimer's, attention deficit hyperactivity, Parkinsons and Schizophrenia.
The company has so far filed 25 product patents under PCT out of which 10 have entered national phase. These are the first product patents granted to Suven from four years of drug discovery efforts, the release added.